-
2
-
-
0037924354
-
Metastatic colorectal cancer: Integrating irinotecan into combination and sequential chemotherapy
-
Douillard JY, Sobrero A, Carnaghi C, et al: Metastatic colorectal cancer: Integrating irinotecan into combination and sequential chemotherapy. Ann Oncol 14:ii7-ii12, 2003 (Pubitemid 36874132)
-
(2003)
Annals of Oncology
, vol.14
, Issue.SUPPL. 2
-
-
Douillard, J.-Y.1
Sobrero, A.2
Carnaghi, C.3
Comella, P.4
Diaz-Rubio, E.5
Santoro, A.6
Van Cutsem, E.7
-
3
-
-
33746805967
-
Randomized controlled trial of reduced-dose bolus fluorouracil plus leucovorin and irinotecan or infused fluorouracil plus leucovorin and oxaliplatin in patients with previously untreated metastatic colorectal cancer: A North American intergroup trial
-
DOI 10.1200/JCO.2006.06.1317
-
Goldberg RM, Sargent DJ, Morton RF, et al: Randomized controlled trial of reduced-dose bolus fluorouracil plus leucovorin and irinotecan or infused fluorouracil plus leucovorin and oxaliplatin in patients with previously untreated metastatic colorectal cancer: A North American Intergroup Trial. J Clin Oncol 24:3347-3353, 2006 (Pubitemid 46638888)
-
(2006)
Journal of Clinical Oncology
, vol.24
, Issue.21
, pp. 3347-3353
-
-
Goldberg, R.M.1
Sargent, D.J.2
Morton, R.F.3
Fuchs, C.S.4
Ramanathan, R.K.5
Williamson, S.K.6
Findlay, B.P.7
Pitot, H.C.8
Alberts, S.9
-
4
-
-
1342290189
-
FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: A randomized GERCOR study
-
DOI 10.1200/JCO.2004.05.113
-
Tournigand C, André T, Achille E, et al: FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: A randomized GERCOR study. J Clin Oncol 22:229-237, 2004 (Pubitemid 41095086)
-
(2004)
Journal of Clinical Oncology
, vol.22
, Issue.2
, pp. 229-237
-
-
Tournigand, C.1
Andre, T.2
Achille, E.3
Lledo, G.4
Flesh, M.5
Mery-Mignard, D.6
Quinaux, E.7
Couteau, C.8
Buyse, M.9
Ganem, G.10
Landi, B.11
Colin, P.12
Louvet, C.13
De Gramont, A.14
-
5
-
-
42949149159
-
Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: A randomized phase III study
-
Saltz LB, Clarke S, Díaz-Rubio E, et al: Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: A randomized phase III study. J Clin Oncol 20:2013-2019, 2008
-
(2008)
J Clin Oncol
, vol.20
, pp. 2013-2019
-
-
Saltz, L.B.1
Clarke, S.2
Díaz-Rubio, E.3
-
6
-
-
12244301581
-
In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: Determination of a pharmacokinetic/pharmacodynamic relationship
-
Mendel DB, Laird AD, Xin X, et al: In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: Determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 9:327-337, 2003 (Pubitemid 36109749)
-
(2003)
Clinical Cancer Research
, vol.9
, Issue.1 I
, pp. 327-337
-
-
Mendel, D.B.1
Douglas, L.A.2
Xin, X.3
Louie, S.G.4
Christensen, J.G.5
Li, G.6
Schreck, R.E.7
Abrams, T.J.8
Ngai, T.J.9
Lee, L.B.10
Murray, L.J.11
Carver, J.12
Chan, E.13
Moss, K.G.14
Haznedar, J.O.15
Sukbuntherng, J.16
Blake, R.A.17
Sun, L.18
Tang, C.19
Miller, T.20
Shirazian, S.21
McMahon, G.22
Cherrington, J.M.23
more..
-
7
-
-
9144274970
-
SU11248 inhibits tumor growth and CSF-1R-dependent osteolysis in an experimental breast cancer bone metastasis model
-
DOI 10.1023/B:CLIN.0000006873.65590.68
-
Murray LJ, Abrams TJ, Long KR, et al: SU11248 inhibits tumor growth and CSF-1R-dependent osteolysis in an experimental breast cancer bone metastasis model. Clin Exp Metastasis 20:757-766, 2003 (Pubitemid 38019277)
-
(2003)
Clinical and Experimental Metastasis
, vol.20
, Issue.8
, pp. 757-766
-
-
Murray, L.J.1
Abrams, T.J.2
Long, K.R.3
Ngai, T.J.4
Olson, L.M.5
Hong, W.6
Keast, P.K.7
Brassard, J.A.8
O'Farrell, A.M.9
Cherrington, J.M.10
Pryer, N.K.11
-
8
-
-
33749544080
-
An orally administered multitarget tyrosine kinase inhibitor, SU11248, is a novel potent inhibitor of thyroid oncogenic RET/papillary thyroid cancer kinases
-
DOI 10.1210/jc.2005-2845
-
Kim DW, Jo YS, Jung HS, et al: An orally administered multitarget tyrosine kinase inhibitor, SU11248, is a novel potent inhibitor of thyroid oncogenic RET/papillary thyroid cancer kinases. J Clin Endocrinol Metab 91:4070-4076, 2006 (Pubitemid 44536887)
-
(2006)
Journal of Clinical Endocrinology and Metabolism
, vol.91
, Issue.10
, pp. 4070-4076
-
-
Dong, W.K.1
Young, S.J.2
Hye, S.J.3
Hyo, K.C.4
Jung, H.S.5
Ki, C.P.6
Su, H.P.7
Jung, H.H.8
So, Y.R.9
Gi, R.K.10
Lee, S.-J.11
Jo, K.-W.12
Shong, M.13
-
9
-
-
78650874372
-
SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer
-
Abrams TJ, Lee LB, Murray LJ, et al: SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer. Mol Cancer Ther 2:471-478, 2003
-
(2003)
Mol Cancer Ther
, vol.2
, pp. 471-478
-
-
Abrams, T.J.1
Lee, L.B.2
Murray, L.J.3
-
10
-
-
0038204144
-
SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo
-
DOI 10.1182/blood-2002-07-2307
-
O'Farrell AM, Abrams TJ, Yuen HA, et al: SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. Blood 101:3597-3605, 2003 (Pubitemid 36857948)
-
(2003)
Blood
, vol.101
, Issue.9
, pp. 3597-3605
-
-
O'Farrell, A.-M.1
Abrams, T.J.2
Yuen, H.A.3
Ngai, T.J.4
Louie, S.G.5
Yee, K.W.H.6
Wong, L.M.7
Hong, W.8
Lee, L.B.9
Town, A.10
Smolich, B.D.11
Manning, W.C.12
Murray, L.J.13
Heinrich, M.C.14
Cherrington, J.M.15
-
12
-
-
36048992408
-
Phase II trial of sunitinib in patients with metastatic colorectal cancer after failure of standard therapy
-
DOI 10.1200/JCO.2007.12.8637
-
Saltz LB, Rosen LS, Marshall JL, et al: Phase II trial of sunitinib in patients with metastatic colorectal cancer after failure of standard therapy. J Clin Oncol 25:4793-4799, 2007 (Pubitemid 350086483)
-
(2007)
Journal of Clinical Oncology
, vol.25
, Issue.30
, pp. 4793-4799
-
-
Saltz, L.B.1
Rosen, L.S.2
Marshall, J.L.3
Belt, R.J.4
Hurwitz, H.I.5
Eckhardt, S.G.6
Bergsland, E.K.7
Haller, D.G.8
Lockhart, A.C.9
Rocha, L.C.M.10
Huang, X.11
DePrimo, S.E.12
Chow-Maneval, E.13
Chao, R.C.14
Lenz, H.J.15
-
13
-
-
84855168247
-
A phase I study of sunitinib in combination with FOLFIRI in patients with untreated metastatic colorectal cancer
-
Starling N, Vázquez-Mazón F, Cunningham D, et al: A phase I study of sunitinib in combination with FOLFIRI in patients with untreated metastatic colorectal cancer. Ann Oncol 23:119-127, 2012
-
(2012)
Ann Oncol
, vol.23
, pp. 119-127
-
-
Starling, N.1
Vázquez-Mazón, F.2
Cunningham, D.3
-
14
-
-
0034594628
-
New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada
-
Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216, 2000
-
(2000)
J Natl Cancer Inst
, vol.92
, pp. 205-216
-
-
Therasse, P.1
Arbuck, S.G.2
Eisenhauer, E.A.3
-
15
-
-
0018687930
-
A multiple testing procedure for clinical trials
-
DOI 10.2307/2530245
-
O'Brien PC, Fleming TR: A multiple testing procedure for clinical trials. Biometrics 35:549-556, 1979 (Pubitemid 10242750)
-
(1979)
Biometrics
, vol.35
, Issue.3
, pp. 549-556
-
-
O'Brien, P.C.1
Fleming, T.R.2
-
16
-
-
84876076798
-
Application of adaptive study designs: Phase II and III results from the cediranib (CED) HORIZON (HZ) II and III studies
-
abstr 3633∧
-
Wilson D, Hoff PM, Schmoll H, et al: Application of adaptive study designs: Phase II and III results from the cediranib (CED) HORIZON (HZ) II and III studies. J Clin Oncol 29:254s, 2011 (suppl; abstr 3633∧)
-
(2011)
J Clin Oncol
, vol.29
, Issue.SUPPL.
-
-
Wilson, D.1
Hoff, P.M.2
Schmoll, H.3
-
17
-
-
79956334386
-
Randomized, placebo-controlled, phase III study of first-line oxaliplatin-based chemotherapy plus PTK787/ZK 222584, an oral vascular endothelial growth factor receptor inhibitor, in patients with metastatic colorectal adenocarcinoma
-
Hecht JR, Trarbach T, Hainsworth JD, et al: Randomized, placebo-controlled, phase III study of first-line oxaliplatin-based chemotherapy plus PTK787/ZK 222584, an oral vascular endothelial growth factor receptor inhibitor, in patients with metastatic colorectal adenocarcinoma. J Clin Oncol 29:1997-2003, 2011
-
(2011)
J Clin Oncol
, vol.29
, pp. 1997-2003
-
-
Hecht, J.R.1
Trarbach, T.2
Hainsworth, J.D.3
-
18
-
-
67650996205
-
Phase IV study of bevacizumab in combination with infusional fluorouracil, leucovorin and irinotecan (FOLFIRI) in first-line metastatic colorectal cancer
-
Sobrero A, Ackland S, Clarke S, et al: Phase IV study of bevacizumab in combination with infusional fluorouracil, leucovorin and irinotecan (FOLFIRI) in first-line metastatic colorectal cancer. Oncology 77:113-119, 2009
-
(2009)
Oncology
, vol.77
, pp. 113-119
-
-
Sobrero, A.1
Ackland, S.2
Clarke, S.3
-
19
-
-
36048960109
-
Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: Results from the BICC-C study
-
DOI 10.1200/JCO.2007.11.3357
-
Fuchs CS, Marshall J, Mitchell E, et al: Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in firstline treatment of metastatic colorectal cancer: Results from the BICC-C Study. J Clin Oncol 25:4779-4786, 2007 (Pubitemid 350086481)
-
(2007)
Journal of Clinical Oncology
, vol.25
, Issue.30
, pp. 4779-4786
-
-
Fuchs, C.S.1
Marshall, J.2
Mitchell, E.3
Wierzbicki, R.4
Ganju, V.5
Jeffery, M.6
Schulz, J.7
Richards, D.8
Soufi-Mahjoubi, R.9
Wang, B.10
Barrueco, J.11
-
20
-
-
75749096309
-
Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: Efficacy and circulating angiogenic biomarkers associated with therapeutic resistance
-
Kopetz S, Hoff PM, Morris JS, et al: Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: Efficacy and circulating angiogenic biomarkers associated with therapeutic resistance. J Clin Oncol 28:453-459, 2010
-
(2010)
J Clin Oncol
, vol.28
, pp. 453-459
-
-
Kopetz, S.1
Hoff, P.M.2
Morris, J.S.3
-
21
-
-
79956297102
-
Randomized, placebo-controlled, phase III study of oxaliplatin, fluorouracil, and leucovorin with or without PTK787/ZK 222584 in patients with previously treated metastatic colorectal adenocarcinoma
-
Van Cutsem E, Bajetta E, Valle J, et al: Randomized, placebo-controlled, phase III study of oxaliplatin, fluorouracil, and leucovorin with or without PTK787/ZK 222584 in patients with previously treated metastatic colorectal adenocarcinoma. J Clin Oncol 29:2004-2010, 2011
-
(2011)
J Clin Oncol
, vol.29
, pp. 2004-2010
-
-
Van Cutsem, E.1
Bajetta, E.2
Valle, J.3
-
22
-
-
77953033291
-
Relationship between exposure to sunitinib and efficacy and tolerability end points in patients with cancer: Results of a pharmacokinetic/pharmacodynamic meta-analysis
-
Houk BE, Bello CL, Poland B, et al: Relationship between exposure to sunitinib and efficacy and tolerability end points in patients with cancer: Results of a pharmacokinetic/pharmacodynamic meta-analysis. Cancer Chemother Pharmacol 66:357-371, 2010
-
(2010)
Cancer Chemother Pharmacol
, vol.66
, pp. 357-371
-
-
Houk, B.E.1
Bello, C.L.2
Poland, B.3
|